AstraZeneca’s NeoCOAST-2 Study: A New Frontier in Lung Cancer Treatment

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca, in collaboration with Parexel International, is conducting a Phase II study titled ‘NeoCOAST-2’ to evaluate the safety and efficacy of various drug combinations in treating resectable, early-stage non-small cell lung cancer (NSCLC). The study aims to explore the potential of neoadjuvant and adjuvant treatments in improving patient outcomes.

The study tests several interventions, including Durvalumab combined with Oleclumab, Monalizumab, or AZD0171, and platinum doublet chemotherapy. Other combinations involve Volrustomig, Rilvegostomig, and Datopotamab deruxtecan (Dato-DXd) with chemotherapy, aiming to enhance the treatment efficacy for NSCLC patients.

This open-label, randomized study follows a parallel intervention model without masking, focusing primarily on treatment. Participants are allocated to different treatment arms to assess the impact of each drug combination.

The study began on April 14, 2022, with primary completion expected by 2025. The latest update was submitted on August 7, 2025, indicating ongoing recruitment and progress.

For investors, this study could influence AstraZeneca’s stock performance positively, as successful outcomes may enhance their oncology portfolio. The competitive landscape in NSCLC treatment remains intense, with several companies vying for market share.

The study is ongoing, with further details available on the ClinicalTrials portal.